Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TYRA-300 |
Synonyms | |
Therapy Description |
TYRA-300 selectively inhibits FGFR3, potentially leading to decreased tumor growth (Annals of Oncology 33 (2022): S751). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TYRA-300 | TYRA300|TYRA 300 | FGFR3 Inhibitor 19 | TYRA-300 selectively inhibits FGFR3, potentially leading to decreased tumor growth (Annals of Oncology 33 (2022): S751). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR3 S249C | urinary bladder cancer | predicted - sensitive | TYRA-300 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, TYRA-300 induced tumor regression a cell line xenograft model of bladder cancer harboring FGFR3 S249C (Annals of Oncology 33 (2022): S751). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05544552 | Phase Ib/II | TYRA-300 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations (SURF301) | Recruiting | USA | FRA | ESP | AUS | 0 |